| http://www.w3.org/ns/prov#value | - He writes, ???Their evaluation was not based on a rigorous study of the specificity and sensitivity of the test??? and adds that FDA did not evaluate the risks and benefits associated with the test.Dr Ablin identifies 4 fundamental cruxes: PSA is not cancer-specific, prostate cancer is an age-related disease, the PSA test cannot distinguish an indolent from an aggressive cancer, and there is no le
|
